MA29700B1 - Vaccin - Google Patents

Vaccin

Info

Publication number
MA29700B1
MA29700B1 MA30653A MA30653A MA29700B1 MA 29700 B1 MA29700 B1 MA 29700B1 MA 30653 A MA30653 A MA 30653A MA 30653 A MA30653 A MA 30653A MA 29700 B1 MA29700 B1 MA 29700B1
Authority
MA
Morocco
Prior art keywords
type
rotavirus strain
immune response
response against
vaccine
Prior art date
Application number
MA30653A
Other languages
English (en)
Inventor
Brigitte Desiree Alberte Colau
Vos Beatrice Arsene Virginie De
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0516944A external-priority patent/GB0516944D0/en
Priority claimed from GB0521164A external-priority patent/GB0521164D0/en
Priority claimed from GB0608962A external-priority patent/GB0608962D0/en
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of MA29700B1 publication Critical patent/MA29700B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/15—Reoviridae, e.g. calf diarrhea virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne une méthode destinée à induire une réponse immunitaire contre une souche de rotavirus. Cette méthode consiste à administrer à un sujet une composition comprenant une souche de rotavirus atténuée de type GxPy, cette composition générant une réponse immunitaire contre une souche de rotavirus qui n'est ni de type Gx ni de type Py.
MA30653A 2005-08-17 2008-02-13 Vaccin MA29700B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0516944A GB0516944D0 (en) 2005-08-17 2005-08-17 Vaccine
GB0521164A GB0521164D0 (en) 2005-10-18 2005-10-18 Vaccine
GB0608962A GB0608962D0 (en) 2006-05-05 2006-05-05 Vaccine

Publications (1)

Publication Number Publication Date
MA29700B1 true MA29700B1 (fr) 2008-08-01

Family

ID=37757924

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30653A MA29700B1 (fr) 2005-08-17 2008-02-13 Vaccin

Country Status (25)

Country Link
US (1) US20090028828A1 (fr)
EP (2) EP1915173A2 (fr)
JP (1) JP5519934B2 (fr)
KR (1) KR20080036648A (fr)
AR (1) AR054916A1 (fr)
AU (1) AU2006281566B2 (fr)
BR (1) BRPI0615203A2 (fr)
CA (1) CA2619751C (fr)
CR (1) CR9759A (fr)
CY (1) CY1116135T1 (fr)
DK (1) DK2233153T3 (fr)
EA (1) EA014328B1 (fr)
ES (1) ES2534637T3 (fr)
HR (1) HRP20150310T1 (fr)
IL (1) IL189289A0 (fr)
MA (1) MA29700B1 (fr)
MX (1) MX2008002270A (fr)
NO (1) NO20080754L (fr)
PE (1) PE20070235A1 (fr)
PL (1) PL2233153T3 (fr)
PT (1) PT2233153E (fr)
SG (1) SG163571A1 (fr)
SI (1) SI2233153T1 (fr)
TW (1) TW200740457A (fr)
WO (1) WO2007020078A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0107510D0 (en) 2001-03-26 2001-05-16 Univ Bristol New elongase gene and a process for the production of -9-polyunsaturated fatty acids
EP2197283B1 (fr) * 2007-09-25 2013-07-17 Aridis Pharmaceuticals Formulations pour la préservation de rotavirus
US9311112B2 (en) * 2009-03-16 2016-04-12 Apple Inc. Event recognition
EP2701735A4 (fr) * 2011-04-28 2014-11-26 Internat Medica Foundation Préparations de vaccins liquides
CN104507495A (zh) * 2012-04-23 2015-04-08 巴拉特生物技术国际有限公司 轮状病毒疫苗组合物及其制备方法
CN108431214B (zh) 2015-10-05 2022-03-01 美国政府(由卫生和人类服务部的部长所代表) 人轮状病毒g9p[6]毒株和作为疫苗的用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE170081T1 (de) * 1990-11-16 1998-09-15 Childrens Hosp Medical Center Humane rotativen, impfstoffe und methoden
AU767885B2 (en) * 1999-08-17 2003-11-27 Smithkline Beecham Biologicals (Sa) Vaccine
WO2005021033A2 (fr) * 2003-09-02 2005-03-10 Glaxosmithkline Biologicals S.A. Vaccin

Also Published As

Publication number Publication date
CR9759A (es) 2008-05-05
EP1915173A2 (fr) 2008-04-30
AU2006281566A1 (en) 2007-02-22
PT2233153E (pt) 2015-04-20
TW200740457A (en) 2007-11-01
EP2233153B1 (fr) 2015-01-21
PL2233153T3 (pl) 2015-06-30
NO20080754L (no) 2008-05-15
IL189289A0 (en) 2008-06-05
CY1116135T1 (el) 2017-02-08
ES2534637T3 (es) 2015-04-27
DK2233153T3 (da) 2015-04-27
CA2619751A1 (fr) 2007-02-22
WO2007020078A3 (fr) 2007-05-24
SI2233153T1 (sl) 2015-05-29
SG163571A1 (en) 2010-08-30
AU2006281566B2 (en) 2011-09-01
US20090028828A1 (en) 2009-01-29
JP5519934B2 (ja) 2014-06-11
KR20080036648A (ko) 2008-04-28
CA2619751C (fr) 2016-07-05
EP2233153A1 (fr) 2010-09-29
WO2007020078A2 (fr) 2007-02-22
JP2009504701A (ja) 2009-02-05
AR054916A1 (es) 2007-07-25
PE20070235A1 (es) 2007-04-04
HRP20150310T1 (hr) 2015-06-19
EA200800320A1 (ru) 2008-10-30
MX2008002270A (es) 2008-03-27
EA014328B1 (ru) 2010-10-29
BRPI0615203A2 (pt) 2011-05-10

Similar Documents

Publication Publication Date Title
MA29700B1 (fr) Vaccin
MA29459B1 (fr) Vaccins
MA29569B1 (fr) Composition immunogene
DK1836312T3 (da) Fremgangsmåder og sammensætninger til diagnosticeringer af aldersrelateret makulær degeneration
UA92505C2 (ru) Композиции на основе антитела против cd3
WO2005016235A3 (fr) Utilisation combinee d'inhibiteurs de l'inosine monophosphate deshydrogenase (impdh) et d'agonistes du toll-like recepteur
MA30531B1 (fr) Anticorps anti-dll4 et leurs procedes d'utilisation
MX2008009929A (es) Vacuna a base de levadura para inducir una respuesta inmune.
ATE426412T1 (de) Adjuvante influenza-vakzine
MA31502B1 (fr) Anticorps anti-notch 1 specifiques a nrr et ses procedes d'utilisation
WO2008014979A3 (fr) Acide nucléique de formule (i): gixmgn, ou(ii): cixmcn, en particulier en tant qu'agent/adjuvant immunostimulant
NO20092023L (no) Oligoribonuleotider og anvendelser derav
BRPI0510430A (pt) composições e métodos para vacinação mucosal
PT1268498E (pt) Fosfonatos cardioprotectores
TW200726479A (en) Method of inducing neutralizing antibodies to human immunodeficiency virus
DE602006011859D1 (de) T-cd4+-epitope der latenzantigene typ i und ii des epstein-barr-virus, die bei der mehrzahl von individuen in der kaukasischen bevölkerung erkannt werden können, und anwendungen davon
PL1758555T3 (pl) Czynnik tworzący oleożel zawierający triterpen, oleożel zawierający triterpen oraz sposób wytwarzania oleożelu zawierającego triterpen
SG162818A1 (en) Multivalent entrain-and-amplify immunotherapeutics for carcinoma
FR3064264B1 (fr) Composition a base de tetrafluoropropene
PT1879612E (pt) Utilização de péptidos nativos e de seus derivados optimizados em vacinação
ATE374555T1 (de) Kaffeemaschine
WO2019191586A3 (fr) Poliovirus inactivé par irradiation, compositions les comprenant, et procédés de préparation
PL1648412T3 (pl) Mikroemulsje i ich zastosowanie do zapobiegania chorobom dróg oddechowych
TW200609559A (en) Contact lenses and methods for their design
SG147465A1 (en) Vaccine